Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tailored brain stimulation quiet anxiety that drugs Can't?

NCT ID NCT07801391

Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are testing whether a personalized form of brain stimulation can ease symptoms in people with anxiety disorders that have not improved with standard treatments. The approach uses a device to deliver rapid magnetic pulses to specific brain circuits, guided by each person's own brain map. The study will measure changes in anxiety and related symptoms before and after the treatment. If successful, this could point toward a new option for those who have run out of effective therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Personalized, neuronavigated accelerated intermittent theta burst stimulation (aiTBS) delivered via a transcranial magnetic stimulation device
What this could lead to
If it works, this could offer a new, non-drug option for people with anxiety disorders that do not respond to standard treatments, potentially easing symptoms and improving daily life.
What could go wrong
This is a small, early-stage study with no control group, so results may not apply broadly. The treatment may not relieve symptoms for everyone, and TMS can cause side effects like scalp discomfort or headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male/ female aged ≥ 21 years and ≤ 70 years * Diagnosis of an anxiety-related disorder as validated by the MINI (Specifically, the types of anxiety-related disorders are: generalized anxiety disorder; panic disorderl social anxiety disorder; obsessive compulsive disorder; post-traumatic stress disorder; agoraphobia; anxiety disorder due to another medical condition; other specified anxiety disorders; and unspecified anxiety disorder.) * Non-response to adequate trial (4 weeks) of at least two anxiety medication as verified by the study clinician, or psychotherapy for anxiety * BAI score of 16 or above * Able to give informed consent * Able to understand English Exclusion Criteria: * DSM-5 psychotic disorder * Significant personality disorder which may hinder the progress of this study * Drug or alcohol abuse or dependency (preceding 3 months) * Rapid clinical response required, e.g., high suicide risk * Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy * Metal in the cranium, skull defects, pacemaker, cochlear implant, medication infusion pumps or any other electronic implants/ devices * Tattoos containing derromagnetic ink or permanent piercings * Currently wearing dental braces * Pregnancy * Unsuitable for MRI or TMS for any other reasons * With recent TMS or ECT treatment within the past 3 months * Currently on multiple stimulant medications (2 or more) * Participant does not have the capacity to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Agoraphobia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agoraphobia anxiety disorder generalized anxiety disorder obsessive-compulsive disorder panic disorder post-traumatic stress disorder social phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety and fear-related disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National University Hospital, Singapore

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.